Economic Impacts and Pricing Strategies Surrounding Biosimilars

EP: 1.Biologics Utilization Impacting US Health Care Spending

EP: 2.Current Landscape of Biosimilar Use in US Healthcare Space

EP: 3.Interchangeability Impacting Biosimilar Uptake

EP: 4.The Impact of Payer Coverage and Reimbursement on Biosimilars

EP: 5.Navigating Biosimilar Uptake in New Patients

Now Viewing

EP: 6.Economic Impacts and Pricing Strategies Surrounding Biosimilars

EP: 7.Private Label Biosimilars

EP: 8.Biosimilars in the Commercial Sector

EP: 9.The Influence of Employer Preferences And Adoption of Biosimilars

EP: 10.Out of Pocket Costs Associated with Biosimilar Use

EP: 11.Unmet Needs and Future Initiatives

EP: 12.Ideal Goals for Biosimilar Utilization

EP: 13.Foreseeable Biosimilar Trends

EP: 14.Legislative Support for Biosimilars

EP: 15.Key Takeaways for Biosimilar Utilization

Video content above is prompted by the following:

• What economic impacts do biosimilars have in different delivery channels (inpatient, self-administered outpatient, outpatient infusion)?
• How do pricing strategies for biosimilars, such as the high and low list prices of adalimumab biosimilars, affect their market penetration and adoption?
  • How do biosimilar pricing strategies affect patient access and affordability?
  • Are there more effective pricing models that could be adopted?
  • Are there certain customer subtypes that will want a rebate drive model vs. those want a rebate driven model vs. a WAC driven model?